[{"address1": "4149 Liberty Canyon Road", "city": "Agoura Hills", "state": "CA", "zip": "91301", "country": "United States", "phone": "805-730-0360", "website": "https://www.acelyrin.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.", "fullTimeEmployees": 135, "companyOfficers": [{"maxAge": 1, "name": "Ms. Mina  Kim J.D.", "age": 50, "title": "CEO & Director", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tyler  Marciniak", "title": "Head of Investor Relations & Communications", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. K. Amar Murugan J.D.", "age": 49, "title": "Chief Legal Officer", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Chow", "title": "Chief People Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Suzy  Buckhalter CPA", "title": "Senior Director of Finance & Accounting", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kenneth A. Lock", "age": 50, "title": "Chief Commercial Officer", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shephard  Mpofu M.D.", "title": "Chief Medical Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Patricia A. Turney", "age": 57, "title": "Chief Technical Operations Officer", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 4, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1735689600, "maxAge": 86400, "priceHint": 4, "previousClose": 1.99, "open": 2.01, "dayLow": 1.925, "dayHigh": 2.04, "regularMarketPreviousClose": 1.99, "regularMarketOpen": 2.01, "regularMarketDayLow": 1.925, "regularMarketDayHigh": 2.04, "forwardPE": -0.8792743, "volume": 754275, "regularMarketVolume": 754275, "averageVolume": 941611, "averageVolume10days": 2635540, "averageDailyVolume10Day": 2635540, "bid": 1.96, "ask": 2.04, "bidSize": 200, "askSize": 200, "marketCap": 199648736, "fiftyTwoWeekLow": 1.91, "fiftyTwoWeekHigh": 8.885, "fiftyDayAverage": 3.917, "twoHundredDayAverage": 4.748075, "currency": "USD", "enterpriseValue": -357141952, "floatShares": 64322149, "sharesOutstanding": 100326000, "sharesShort": 6141478, "sharesShortPriorMonth": 5718785, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.0612, "heldPercentInsiders": 0.08031, "heldPercentInstitutions": 0.99428004, "shortRatio": 7.76, "shortPercentOfFloat": 0.0698, "impliedSharesOutstanding": 100326000, "bookValue": 5.292, "priceToBook": 0.37603933, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -264404992, "trailingEps": -2.46, "forwardEps": -2.12, "enterpriseToEbitda": 0.957, "52WeekChange": -0.698941, "SandP52WeekChange": 0.23631513, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "SLRN", "underlyingSymbol": "SLRN", "shortName": "ACELYRIN, INC.", "longName": "Acelyrin, Inc.", "firstTradeDateEpochUtc": 1683207000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "331b354b-7a4d-3b82-ac00-9819e1a01b9d", "messageBoardId": "finmb_698766339", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.99, "targetHighPrice": 20.0, "targetLowPrice": 3.0, "targetMeanPrice": 9.16667, "targetMedianPrice": 7.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 562372992, "totalCashPerShare": 5.633, "ebitda": -373011008, "totalDebt": 6558000, "quickRatio": 6.737, "currentRatio": 7.147, "debtToEquity": 1.241, "returnOnAssets": -0.32891998, "returnOnEquity": -0.41946998, "freeCashflow": -229127008, "operatingCashflow": -255968992, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-18"}]